当前位置：药药网 / 数据中心 / 临床注释-2,变异和临床注释数据
卡培他滨
临床注释ID
1451274165
药物名称(英)
capecitabine
变异单倍型
rs75017182
基因
DPYD
证据级别
1A
水平覆盖
水平修饰符
Tier 1 VIP
表现型类别(英)
Toxicity
表现型类别
毒性
分数
200
PMID计数
6
计数的证据
8
表现型
肿瘤
表现型(英)
Neoplasms
最新日期
2021/5/24 0:00:00
URL
https://www.pharmgkb.org/clinicalAnnotation/1451274165
专业人口(英)
专业人口
临床等位基因
id等位基因注释文本
1302 GG The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the Hap3B allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1301 CG The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the Hap3B allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
1300 CC The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the Hap3B allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.
临床证据
id证据的ID总结
1091 1449162097 Genotype CG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype GG.
1090 1449161752 Genotype GG is not associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.
1089 1447954949 Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.
1088 1444698794 Genotype CG is not associated with severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.
1087 1184471970 Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.
1086 1183681878 Genotype CG is not associated with severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.
1085 PA166104963 Annotation of DPWG Guideline for capecitabine and DPYD
1084 PA166109594 Annotation of CPIC Guideline for capecitabine and DPYD
临床病史
id类型评论
1432 Update Added DPWG guideline as evidence
1431 Update CA score added as part of scoring system release. LOE assigned following curator review.
1430 Update Added rs number to text
1429 Update Fixed case usage typo in CPIC assignment.
1428 Update Added CPIC function and modified text.
1427 Update Attached CPIC guideline and removed override.
1426 Create Created

最新招商产品更多>>

网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3